Search results
Showing 241 to 255 of 1257 results for pathway
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)
Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.
Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)
Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.
Evidence-based recommendations on blinatumomab (Blincyto) with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia in adults.
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)
Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in adults.
Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)
Evidence-based recommendations on pralsetinib (Gavreto) for treating RET fusion-positive advanced non-small-cell lung cancer in adults.
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)
Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.
NICE has developed a medtech innovation briefing (MIB) on RenalSense Clarity RMS for acute kidney injury .
Brain tumours (primary) and brain metastases in over 16s (NG99)
This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
Supporting the health and care system to implement virtual wards
Virtual wards (also known as hospital at home) provide hospital level care at home.
for the relative effectiveness of treatment options at this stage in the pathway of care. It is recommended that studies be undertaken...
Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)
Evidence-based recommendations on cipaglucosidase alfa (Pombiliti) with miglustat (Opfolda) for treating late-onset Pompe disease in adults.